Finch Therapeutics Group, Inc.
FNCH · OTC
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $3 | $0 |
| % Growth | – | -100% | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | – | -1.5% | – |
| R&D Expenses | $0 | $0 | $2 | $0 |
| G&A Expenses | $6 | $5 | $5 | $4 |
| SG&A Expenses | $6 | $5 | $5 | $4 |
| Sales & Mktg Exp. | $0 | -$0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | -$2 | $0 |
| Operating Expenses | $6 | $5 | $5 | $4 |
| Operating Income | -$6 | -$5 | -$5 | -$4 |
| % Margin | – | – | -164.5% | – |
| Other Income/Exp. Net | $1 | $1 | $2 | $1 |
| Pre-Tax Income | -$5 | -$4 | -$3 | -$2 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$5 | -$4 | -$3 | -$2 |
| % Margin | – | – | -106.9% | – |
| EPS | -3.01 | -2.41 | -1.89 | -1.51 |
| % Growth | -24.9% | -27.5% | -25.2% | – |
| EPS Diluted | -3.01 | -2.41 | -1.89 | -1.51 |
| Weighted Avg Shares Out | 2 | 2 | 2 | 2 |
| Weighted Avg Shares Out Dil | 2 | 2 | 2 | 2 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$6 | -$5 | -$5 | -$4 |
| % Margin | – | – | -163% | – |